

2021 Reader on Publicly Available CBMs

November 2021



About this Reader

The exchange of information under the Biological Weapons Convention (BWC) in the form of the Confidence Building Measures (CBMs) is the only permanent transparency and security building mechanism of the BWC.

This Reader, as its forerunners, presents information on CBM-related developments based on the data provided in the openly available CBM declarations of the current year. The CBM Reader, which is an authoritative publication of the University of Hamburg aims to underline the importance of participating in the CBM data exchange as the only established permanent transparency measure for the BWC and to highlight the particular efforts of an increasing number of states to increase transparency by making their CBM submissions available to the public. The CBM Reader series is prepared as part of our efforts to enhance transparency around bioweapon-relevant activities globally. Such transparency is indispensable for building confidence in compliance with the BWC and must extend to all stakeholders including civil society.

For more information please visit: www.biological-arms-control.org/projects_improvingthecbms.html.

Development of the CBM regime in 2021

The last formal decision of States Parties with regard to CBMs dates back to 2011. On the 7th Review Conference in 2011 BWC States Parties decided to address CBMs in the 2012 and 2013 the Meetings of Experts and the Meetings of States Parties. It was aimed to discuss a possible update of the CBM forms (that dates back to the year 1992) in the ISP, but BWC members did not agree on recommendations for a formal decision at the 8th Review Conference. Some States Parties, however, tabled working papers at the ISP and for the 8th Review Conference (see page 3). In general, on the 8th Review Conference in 2016 Member States reached very few forward-looking decisions, and particular no decision was made in relation to CBMs.

Figures shown in this reader also illustrate the need for strengthening the debate of how a more active participation in the mechanism could be reached. The debates in the precedent ISP meetings and at the Review Conference show that these issues have potential for further development.

Facts about the BWC and its CBMs1)

BWC States Parties: 183

Signatory States: 4

New BWC States Parties in 2021: None

States Parties with national contact points: 122

CBMs submitted in 2021: 87 as of 8 November 2021

Public CBMs in 2021: 31 as of 8 November 2021

First-time CBM submission in 2021: Three (not publicly available)

Number of states having participated in the CBM data exchange in 30 years: 119

¹⁾ For reference see data provided by BWC Implementation Support Unit (ISU), accessible at https://documents-dds-ny.un.org/doc/UNDOC/GEN/G19/233/39/PDF/G1923339.pdf?OpenElement

CBM-specific publications in 2021

We could not find any publications on the issue of the CBM mechanism published in 2021.

For earlier publications, please check former versions of this reader at: http://biological-arms-control.org/projects_improvingthecbms.html.

Participation in the CBM regime in 2021

As of 22 November 2021, **92** BWC states parties had submitted their CBM. Therewith the long-time phenomenon that participation is relatively high in years with Review Conferences, but drops down significantly in the following year, does only appear in a moderated form. The overall participation in the CBM mechanism improved slightly over time. Since the beginning of the data exchange in 1987, the annual level of participation was never higher than 50.27 percent of the BWC states parties (183 in total), in 2021 92 of the member states have submitted a CBM, which is an all-time record of CBM submissions for the BWC community. In total, 122 countries submitted a CBM at least once. This means that 60 BWC states parties have yet to submit their first CBM declaration. Continuity in states' participation also remains weak: Only 37 countries have submitted a CBM in each of the past 10 years, and respectively only 31 countries have submitted a CBM once or twice since 1987.

First-time submissions in 2021: Afghanistan (not publicly available), Guatemala (not publicly available), Mozambique (not publicly available).

First-time public submission in 2021: none.


CBM submissions in 2021 (See map 1. in page 7) - States in bold made their CBM available to the public:

1.	Afghanistan	17.	Croatia	32.	India	47.	Malaysia	62.	Oman
2.	Algeria	18.	Cuba	33.	Iran (Islamic	48.	Maldives	63.	Pakistan
3.	Argentina	19.	Cyprus		Republic of)	49.	Mali	64.	Peru
4.	Armenia	20.	Czech Re-	34.	Iraq	50.	Malta	65.	Philippines
5.	Australia		public	35.	Ireland	51.	Mauritius	66.	Poland
6.	Austria	21.	Denmark	36.	Italy	52.	Mexico	67.	Portugal
7.	Azerbaijan	22.	Ecuador	37.	Japan	53.	Mongolia	68.	Qatar
8.	Belarus	23.	El Salvador	38.	Jordan	54.	Montenegro	69.	Rep. Korea
9.	Belgium*	24.	Estonia	39.	Kazakhstan	55.	Morocco	70.	Rep. Mol-
9. 10.	Belgium * Bhutan		Estonia Finland		Kazakhstan Kenya		Morocco Mozambique	70.	Rep. Mol- dova
10.	O	25.		40.		56.			. *
10.	Bhutan Brazil	25. 26.	Finland	40. 41.	Kenya	56. 57.	Mozambique	71.	dova
10. 11.	Bhutan Brazil	25.26.27.	Finland France	40. 41. 42.	Kenya Kyrgyzstan	56. 57.	Mozambique Netherlands	71. 72.	dova Romania
10. 11. 12. 13.	Bhutan Brazil Bulgaria	25.26.27.28.	Finland France Georgia	40. 41. 42. 43.	Kenya Kyrgyzstan Latvia	56. 57. 58.	Mozambique Netherlands New Zea-	71. 72.	dova Romania Russian Fed.
10. 11. 12. 13.	Bhutan Brazil Bulgaria Canada	25.26.27.28.	Finland France Georgia Germany	40. 41. 42. 43. 44.	Kenya Kyrgyzstan Latvia Libya	56.57.58.59.	Mozambique Netherlands New Zea- land	71. 72. 73.	dova Romania Russian Fed. Saudi Ara-

76.	Singapore	80.	Spain	84.	Tajikistan	88.	Ukraine	91.	\mathbf{USA}^*
77.	Slovakia	81.	Suriname	85.	Thailand	89.	United Arab	92.	Uzbekistan
78.	Slovenia	82.	Sweden	86.	Tunisia		Emirates		
79.	South Africa	83.	Switzerland	87.	Turkey	90.	UK		

^{*} States that submitted both public and restricted versions of CBM reports.

Figure 1. CBM submissions per year between 1987 and 2021 (Numbers in this figure may differ from numbers provided by the Implementation Support Unit. This is due to differences in counting states that were formerly part of other states, such as the former republics of the Soviet Union. This figure provides the actual number of CBM declarations submitted in the respective year.)



As of 22 November 2021, 33 countries have made their 2021 CBM declarations publicly available. All of the 33 publicly available CBMs can be found on the website of the Implementation Support Unit (ISU) (https://bwc-ecbm.unog.ch/group/ecbm-portal):

Australia, Austria, Belgium, Bulgaria, Canada (in English and French), Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Ireland, Japan, Latvia, Lithuania, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Portugal, Republic of Moldova, Romania, Saudi Arabia, Serbia, Slovakia, Slovenia, Sweden, Switzerland, Ukraine, United Kingdom and the USA. Belgium and the USA provided two separate versions of their CBMs, one for the restricted part of the ISU website and one for the public.




Table 1. Countries that made their CBM declarations publicly available, 2007-2021

Country	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Albania	_	_	_	X	_		_		_			_			
Australia	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Austria	_	_	X	X	X	X	X		X	X	X	X	X	X	X
Bangladesh	_	X	_		_		_		_				_	_	
Belgium	_	_			X	X	X	X	X	X	X	X	X	X	X
Brazil		_		X											
Bulgaria	X	(x)		(x)	(x)	(x)	(x)	X	X	X	X	X	X	X	X
Canada (En and Fr)		_		_	X	X	X	X	X	X	X	X	X	X	X
Croatia								X				X		X	X
Cyprus	_	_	_		(x)	(x)	_						X	X	X
Czech Republic	_	_	X	X	X	X	X	X	X	X	X	X	X	X	X
Denmark	X	X		X	X	X		X	X	X	X	X	X	X	X
Ecuador					(x)										
Estonia				(x)	(x)		X			X	X	X	X	X	X
Finland	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Georgia			(x)	(x)	(x)										
Germany	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Greece	Λ	A	Λ	Λ	(x)	X	X	Λ	Λ	Λ	Λ	Λ	Λ	Λ	
Hungary					(A)	Λ	Λ	(x)	(x)						
Ireland								(X)							
	X	X	X	X	X				X	X	X	X	X	X	X
Japan Latvia			(x)			X	X	X	X	X	X	X	X	X	X
		()		()	X	X	X	X	X	X	X	X	X	X	X
Liechtenstein	X	(x)	(x)	(x)	(x)		(x)	(x)							
Lithuania	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Luxembourg								(x)	X	X	X	X	X	X	X
Madagascar						(x)									
Malaysia					X										
Mauritius										X					
Mexico									X	X	X	X	X	X	X
Morocco	_	_				_	_	_				_	X		
Myanmar	_	_	_			_				X		X		_	
Netherlands							(x)	X	X	X	X	X	X	X	X
New Zealand	(x)	(x)		(x)	X	X	X	X	X	X	X		X	X	X
Norway		(x)		X	X	X	X		X	X	X	X	X	X	X
Poland				X											
Portugal				X	X	X	X	X	X	X	X	X	X	X	X
Qatar						(x)	(x)								
Republic of Moldova	—				_	X	X	X	X	X		X		X	X
Romania	_	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Saudi Arabia				_		_		_		_		_	_		X
Senegal	_			X											
Serbia	_	_	_	_	_	(x)		(x)	X		X	X	X	X	X
Slovakia	_	_	_	_	_		_	(x)		_	_	X	X	X	X
Slovenia								X	X	X	X	X	X	X	X
Sweden	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Switzerland	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Thailand	_	_	_	(x)	(x)	(x)	_	_					_	_	
Turkey				_	X	X		X	X	X	X	X			
Ukraine					(x)	(x)			X	X	X	X	X	X	X
United Kingdom	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
USA				X	X	X	X	X	X	X	X	X	X	X	X
Total	13	15	14	25	30	29	24	29	30	31	28	32	31	32	33
10001	10	10	17		30		⊿ ⊤		50	31	20	34	<i>J</i> 1	34	33

As shown in **Table 1.**, above, 51 countries have made their CBM publicly available at least once since 2007. "(x)" indicates that states provided their CBM directly to the Hamburg Research Group. Many states make their CBMs publicly available in an erratic way. No explanation readily offers itself for why many states make their CBMs publicly available in one year but not in another.

Summary of data in publicly available 2021 CBM declarations

A summary of the data declared in the publicly available CBMs of 2021 is provided in the table below. More detailed information can be found in the Annex to this Reader. 32 maximum biological containment facilities were declared in publicly available CBMs in 2021, five of which were partially or wholly funded by ministries of defence. 15 of the 30 countries making their 2021 CBM publicly available declared having a biodefence programme; they provided information on 74 biodefence facilities. And lastly, 57 unusual disease outbreaks and 81 vaccine production facilities were declared in the 33 publicly available CBMs of 2021.

Table 2. Summary of data in publicly available CBM declarations, 2021

Form A, part 1: Number of maximum biological containment facilities (BSL-4 or equivalent) declared.

Form A, part 2 (i): Does the state party declare having a biodefence programme? Form A, part 2 (ii): National programmes conducting biological defence research

Form A, part 2 (iii): Number of biodefence facilities declared. Form B (ii): Number of unusual disease outbreaks declared.

Does the state party declare having a past offensive and/or defensive programme? Form F:

Form G: Number of vaccine production facilities declared.

ND / NN: "Nothing to declare" / "Nothing new to declare" indicated in Form X.

Country	Form A, part 1	Form A, part 2 (i)	Form A, part 2 (ii)	Form A, part 2 (iii)	Form B	Form F (off/def)	Form G
Australia	NN (4)	NN (yes)	1	1	NN	NN (no/yes)	2
Austria	1	NN (yes)	21	1	ND	ND	ND
Belgium	ND	yes	1	1	1	ND	2
Bulgaria	ND	ND (no)	ND	ND	ND	NN (no/no)	NN (1)
Canada	2	NN (yes)	2	2	13	NN (yes/yes)	15
Croatia ³	ND (1)	ND	ND	ND (1)	ND^4	ND	ND
Cyprus	NN (0)	NN (no)	NN (0)	NN (0)	NN	NN (no/no)	NN
Czech Republic ⁵	NN	NN	NN	ND	2	NN	NN
Denmark	NN (0)	NN (yes)	NN (1)	1	ND	NN (no/yes)	NN (2)
Estonia	0	ND	ND	ND	1	ND	ND
Finland	0	yes	1	1	ND	ND	ND
Germany	4	yes	2	5	1	NN (no/no)	9
Ireland	NN (1)	NN (no)	NN (0)	NN (0)	NN (0)	ND	NN (3)
Japan	NN (2)	NN (yes)	4	1	ND	NN (no/no)	NN (6)
Latvia	NN (1)	NN	ND	NN (1)	ND	NN (no/yes)	ND
Lithuania	NN (2)	ND	ND	ND	ND	ND	NN
Luxemburg	1	ND	ND	ND	1 ⁶	NN (no/no)	NN (0)

¹ In form 0, Austria has mistakenly ticked both "nothing to declare" and "nothing new to declare".

² Form G is missing.

³ Croatia has ticked "nothing to declare" in form 0, although new data has been introduced in subsequent parts.


⁴ A table reports the occurrence of 30 infectious and parasitic diseases of domestic and wild animals in the Republic of Croatia for

⁵ Czech Republic has partially provided information on forms B and C only.

⁶ Information on possible epidemics of infectious diseases is available on the online site of the National Health Laboratory (via the "Epidemiological surveillance service for infectious diseases"): http://www.lns.public.lu/

Mexico	0	ND	ND	ND	2	ND	2
Netherlands	0	yes	1	1	1	NN (no/yes)	8
New Zealand	ND	ND	ND	ND	NN	NN	ND
Norway	ND	NN (yes)	NN (3)	NN (3)	ND	NN (no/yes)	NN (3)
Portugal	NN (0)	NN (yes)	NN (2)	NN (1)	ND	NN (no/no)	NN (1)
Republic of Moldova		yes	NN	NN	8	NN	ND
Romania	7	ND	_	ND	ND	ND	3
Saudi Arabia*	_	_	_	_	_		_
Serbia ⁷	ND	ND	ND	ND	ND (1)	ND	ND (1)
Slovakia	ND	ND	ND	ND	ND	ND	ND
Slovenia	ND	ND	ND	ND (2)8	ND (1)	ND	ND
Sweden	1	yes	1	2	ND (1)9	NN (no/yes)	NN (1)
Switzerland	4	NN (yes)	2	10	1110	NN (no/yes)	2
Ukraine	ND^{11}	no	ND	1	2	ND	NN (4)
United Kingdom	9	yes	2	1	2^{12}	NN (yes/yes)	7
USA	9	yes	7	29	913	NN (no/—)	11

Map 1. CBM Submissions 2021



https://lns.lu/departement/microbiologie/revilux/

7

⁷ Serbia has ticked "nothing to declare" in form 0, although new data has been introduced in subsequent parts.

⁸ They incorrectly say "nothing to declare".

⁹ The Public Health Agency does not have any deviating outbreaks to report during 2020 apart from the COVID-19 pandemic. ¹⁰ 10 plant diseases and pestis and one human disease (COVID-19).

¹¹ They didn't tick the box but they wrote "nothing to declare".

¹² The UK, like most other countries has suffered from the COVID-19 pandemic caused by SARS-CoV-2. While this is "an outbreak that seems to deviate from the normal pattern", individual case details are not being reported here and datasets on the outbreak in the United Kingdom published by the UK Government's Office for National Statistics.

¹³ Two human disease events and 7 animal disease events.



Research Group for Biological Arms Control

The aim of the Research Group is to contribute, through innovative research and outreach activities, to the universal prevention of biological weapons development, production and use. The focus of activities is twofold. Firstly, the Research Group contributes to preventing the erosion of the universal bioweapons prohibition by opposing norm-harming activities. Secondly, it develops new concepts and instruments for monitoring bioweapon relevant activities and for verifying and enforcing compliance with the norm against bioweapons.

Contact

Research Group for Biological Arms Control

C. F. v. Weizsäcker Centre for Science and Peace Research

University of Hamburg

Bogenallee 11, 20144 Hamburg, Germany Tel +49 40 42838 4383 Fax +49 40 42838 3052

E-mail info@biological-arms-control.org www.biological-arms-control.org

Author

Mochament El Saer

Email: mochament.el_saer@kcl.ac.uk

ANNEX

The following table summarizes the data declared in **CBM Form A, Part 1**, of the publicly available CBM submissions from 2021 (covering 2021) and compares them with the information in publicly available CBMs from 2007 to 2021. The table provides the names and locations of facilities declared in CBM Form A, part 1, their containment levels, the year(s) they were declared, and whether the facilities were wholly or partly funded by the respective ministries of defence (MoD). "ND" indicates that states ticked the "Nothing new to declare" box in Form 0 and provided no further information. "—" indicates that no data was provided or data was not made publicly available (either on the ISU—website or by providing the Hamburg Research Group with the CBM) in the respective year. Cells with background colour indicate that data applies to all cells.

Country									Year o	of Decl	aration	1						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	1. Australian Centre for Disease Preparedness (East Geelong)	BL4	X	X	X	X		X	X								x ¹	partially ²
Australia	2. National High Security Quarantine Laboratory (Melbourne)	BL4	X	X	X	X	NN	X	X	NN	NN	NN	NN	NN	NN	NN	X	no
Australia	3. Queensland Health and Forensic Scientific Services (Coopers Plains)	BL4	X	X	X	X	ININ	X	X	ININ	ININ	ININ	ININ	ININ	ININ	ININ	X	no
	4. Emerging Infectious Disease and Biohazard Response Unit (Westmead)	BL4		X	X	X		X	X								X	no
Austria	Federal Ministry of Defence and Sport (Vienna)	BL3			X	X	X	X	X	X	X	X	X	X	X	X	X	wholly
Belgium	Laboratoire Fédéral d'Orientation (FOL) (FOL) de la défense (DLD)	BL3	—	—	—	_	ND	ND	ND	ND	X	X	X	ND	ND	ND	X	partly
	1. National Center of Infectious and Parastic Diseases (Yanko Sakazov Blvd., Sofia)	BL3	X	X		X	X	X	X			X						
Bulgaria	2. Department of Microbiology and Virology, Military Medical Academy (St. Georgi Sofiiski Str., Sofia)	BL3				_		_	_	NN	NN	X	NN	NN	X	_	NN	NN
	3. National Diagnostic Research Veterinary Medicine Institute (Pencho Slaveikov Blvd., Sofia)	BL3	_			X	X	_	_			X			X			



¹ Although Australia ticked "nothing to declare" in form 0, it modified the name of a facility and MoD's findings details.

² Funding to support ACDP's work on the environmental stability of SARS—CoV—2 was provided in 2020 by Department of Defence.

									rear	or Deci	aratioi	1						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
Canada	National Microbiology Laboratory (Winnipeg)	BL4		_			X	NN	NN	NN	X	X	NN	NN	X	X	X	no
	2. National Center for Foreign Animal Disease (Winnipeg)	BL4					X	_ ,_ ,			X	X			X	X	X	no
Croatia	University Hospital for Infectious Diseases (Zagreb) ³	BL3	_		_		_	_	_	ND	_	_	_	ND		X	X	no
Cyprus	Nothing to declare			—		_	ND	ND			—			—	NN	NN	NN	
	1. State Veterinary Institute Jihlava (Jihlava)	BL3	_				X	_		_								_
	2. State Veterinary Institute Prague (Lysolaje)	BL3					x			_								_
	3. Tekro, spol.s.r.o. (Uničov)	BL3					X			_								_
	4. Collection of Animal Pathogenic Microorganisms, Veterinary Research Institute — former Microbiological Laboratory BSL—3 (Brno)	BL3	X	X			x			_								_
	5. Institute of Molecular Pathology (Hradec Králové)	BL3	X	X			X	X		_								_
Czech Rep.	6. Military Health Institute, Biological Defence Department at Techonin — former Central Military Health Institute, Department Těchonín (Těchonín)	BL4	X	X	NN	NN	X	X	NN	X	NN	NN	NN	NN	NN	NN	NN	wholly
	7. Central Military Health Institute, Department Prague (Prague)	BL2	_	_			X	X		_								_
	8. Laboratory for Biological Monitoring and Protection, Department of Biological Protec- tion, National Institute for Nuclear, Chemi- cal and Biological Protection (Milin)	BL4	_	X			X	X		X								no
	9. Laboratory of Molecular Biology (Hradec Králové)	BL2		X			_			_								_



³ Croatia ticked "nothing to declare" but reported a new facility.

	37 44 4 40 444 4 4 4								1 car (or Deci	iai ali0i	1						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	10. Division of Infectious Diseases, Department of Infectious Diseases and Epizootology, Faculty of Veterinary Medicine (Brno) 11. National Institute of Public Health; Cen-	BL3	_	_			X			_								_
	tre of Epidemiology and Microbiology (Šrobárova)	BL3	_	_			X	_		_								_
	12. Bioveta, a.s. (Ivanovice na Hané)	BL3	_	_			X	_		_								_
	Centre for Biosecurity and Bioprepardness — former National Centre for Biological Defence (Copenhagen)	BL2	_	X		X	_											_
Denmark	2. Larger university in Denmark — anonymous (no location provided)	BL3	_	_	_	_	X	ND	ND	ND	ND	ND	ND	NN	NN	NN	NN	no
	3. TB Vaccine Research (Copenhagen)	BL3	_	_		<u> </u>	X											no
	4. QC Bio (Copenhagen)	BL3		_		_	X											no
	5. International Reference Laboratory of Mycobacteriology (Copenhagen)	BL3	_	_		_	X											no
Ecuador	Nothing to declare			_		_	ND	_	_					_		_	_	_
	Joint Laboratories of Tartu University Clinics (Tartu)	BL3										X	X	X	X	X	X	_
	2. Microbiology Laboratory of North—Estonia Regional Hospital	BL3										X	X	X	X	X	X	_
	3. Veterinary & Food Laboratory	BL3										X	X	X	X	X	X	
Estonia	4. Laboratory for Mycobacteriosis of University of Life Sciences	BL3	_	_	_	ND	ND	_	_	_	ND	X	X	X	X	X	X	_
	5. Institute of Biomedicine and Translational Medicine of Tartu University	BL3										_		X	X	X		_
	6. Laboratory of Communicable Diseases of Estonian Health Board	BL3										_	_	X	X	X	X	_
	7. Synlab Eesti	BL3										_	_	X	X	X	X	_
	8. Icosagen Cell Factory OU	BL3	_	_		_		_				_	_	_		_	X	



									1 car	or Deci	aratioi	1						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	9. University of Tartu Institute of Technology	BL3	_	_	_		_	_		_	_	_	_	_	_	_	X	_
	1. Centre for Biothreat Prepardness — Finnish Defence Forces, Centre for Military Medicine, Research and Development Department (Helsinki)	BL3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	wholly
	2. Finnish Institute of Health and Welfare, bacteriological and virological laboratories (Helsinki, Turku)	BL3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no
	3. Yersinia Research Laboratory, University of Helsinki (Helsinki)	BL2	X	X	X	X	X	X	X	X	X	X	_	X	X	X	X	no
Finland	4. Department of Virology, Viral Zoonoses Group, University of Helsinki (Helsinki)	BL3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no
	5. Institute of Biotechnology (Helsinki)	BL3							X									_
	6. Finnish Food Safety Authority (Ruokavirasto) (Helsinki)	BL3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no
	7. Finnish Defence Research Agency (FDRA) (Lakiala)	BL3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	wholly
	8. Department of Food and Environmental Sciences, University of Helsinki (Helsinki)	BL3	_		_					X	X	X	X		_			_
	9. <i>Clostridium botulinum</i> laboratory, University of Helsinki (Helsinki)	BL2	_	_	_	_		_	_	X	X	X	X	X	X	X	X	no
	10. University of Turku, Institute of Biomedicine and Turku University Hospital/TYKS Laboratories	BS3	_	_	_	_	_	_	_	_	_	_	_	_	_	_	X	no
Georgia	1. National Center for Disease Control and Public Health (Tbilisi)	BL2			X	X	X											
	2. Laboratory of Ministry of Agriculture of Georgia (Tbilisi)	BL2			_	X	X											
Germany	1. Bernhard—Nocht—Institut für Tropen- medizin (Hamburg)	BL4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no



	3.7 11 1 00 HILL 1 1								1001			-						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	2. Friedrich—Loeffler—Institut, Federal Research Institute for Animal Health (Insel Riems)	BL4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no
	3. Institute of Virology at the University of Marburg (Marburg)	BL4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	x	no
	4. Centre for Biological Threats and Special Pathogens (Zentrum für Biologische Gefah- ren und Spezielle Pathogene, ZBS) at the Robert Koch Institute	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	X	_
	University of Crete School of Medicine (Heraklion)	BL3					X											
	2. Kapodistrian University of Athens School of Medicine (Athens)	BL3					X											
Greece	3. The National Arbovirus and Hemorrhagic Fever Viruses Reference Laboratory at Arisotelian University of Thessaloniki (Thessaloniki)	BL3	_	_	_	_	X	NN	NN	_	_	_		_	_	_	_	_
	4. Infectious Diseases Hospital (Thessaloniki)	BL3					X											
	5. Hellenic Pasteur Institute (Athens)	BL3					X											
	6. Athens School of Public Health (Athens)	BL3					X											
Hungary	National Center for Epidemiology (Budapest)	BL4	_	_	_	_	_	_	_	X	X	_	_	_	_	_	_	_
	1. University College Dublin, National Viral Reference Laboratory (Dublin)	BL3+	X	X	X	X	X	_		X	X	X		X				no
	2. Public Health Laboratory, Cherry Orchard Hospital (Dublin)	BL3	X	X	X	X	X			X	X	X		X				no
Ireland	3. Department of Agriculture Food and the Marine Laboratories (Celbridge)	BL3+					X	_	_	X	X	X	NN	X	NN	NN	NN	_
	4. National Salmonella Reference Laboratory, National University of Ireland (Galway)	BL3	X	X	X	X	X	_	_	X	X	X		X				_
	5. Galway University Hospital (Galway)	BL3					X	_	_	X	X	X		X				—

									rear o	or Deci	iaratioi	1						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	6. Irish Marine Institute, Oranmore (Galway)	BL2	X	X	X	X	X		_	X	X	X		X				_
	7. Health Research Board Clinical Research Facility, St James' Hospital (Dublin)	BL2	_	_	_	_	X	_	_	X	X	X		X		_		_
Japan	1. Murayama Annex of National Institute of Infectious Diseases — former National In- stitute of Health (Tokyo)	BL4	_	_	_	_	_	X	NN	NN	NN	NN	NN	NN	NN	NN	NN	no
	2. RIKEN Tsukuba Campus (Ibaraki)	BL4						X										no
	1. Riga East University Hospital Latvian Centre of Infectious Diseases, National Mi- crobiology Reference Laboratory (Linezera Street, Riga)	BL3					X	X	X	X	X	X	X	X			NN	no
Latvia	2. Latvian Biomedicine Research and Study centre (Ratsupites, Riga)	BL2	_	_	ND	_	_	_	_	_	_	X	X	X	NN	NN	_	no
	3. Centre for Disease Prevention and Control of Latvia (Duntes Street, Riga)	BL3					_	X	_	_	_	_	_	_			_	
Liechten- stein	Nothing new to declare		NN	NN	NN	NN	NN	_	NN	NN	_	NN	NN	NN	NN	NN	_	NN
	1. National Public Health Surveillance La- boratory — former Microbiological Labora- tory of Vilnius Public Health Centre (Vil- nius)	BL3	X	X	X	X	X	X	X	X							NN	no
Lithuania	2. Laboratory of Centre for Communicable Diseases and AIDS — former Lithuanian AIDS Center Laboratory (Vilnius)	BL2	X	X	X	X		_			NN	NN	NN	NN	NN	NN	_	_
	3. National Food and Veterinary Risk Assessment Institute — former National Veterinary laboratory (Vilnius)	BL3	X	X	X	X	X	X	X	X							NN	no
Luxem- bourg	1. Laboratoire de santé (Dudelange)	BL3	_	_	_	_	_	ND		_	X	NN	NN	NN	NN	NN	X	no
	2. Luxembourg Institute of Health (Eschsur-Alzette)	BL3			_	_			_	_						_	X	
Madagascar	_				_	_												



Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	1. Animal and Plant In vitro Laboratory, Biotechnology Research Institute, Universiti Malaysia Sabah (Kota Kinabalu)	BL3					X											
	2. Biochemistry Laboratory, Biotechnology Research Institute, Universiti Malaysia Sabah (Kota Kinabalu)	BL3					X											
	3. Genomics Laboratory, Biotechnology Research Institute, Universiti Malaysia Sabah (Kota Kinabalu)	BL3					X											
Malaysia	4. Microbiology Laboratory, Biotechnology Research Institute, Universiti Malaysia Sabah (Kota Kinabalu) 5. Natural Product Chemistry Laboratory,	BL3	_	_			X											
iviaiaysia	Biotechnology Research Institute, Universiti Malaysia Sabah (Kota Kinabalu)	BL3					X											
	6. Medical Laboratories for medical microbiology, parasitology and virology (Serdang)	BL2					X											
	7. Biosafety Level 3, Animal Biosafety Level 3 Laboratory (Serdang)	BL3					X											
	8. Plant Biotech Facility, Centre for Research in Biotechnology for Agriculture (Kuala Lumpur)	_					X											
	9. Institute for Systems Biology (Bangi)	BL2					X											
	10. Veterinary Resarch Institute (Ipoh)	BL3					X											
Mauritius	_	_	—	—	—	—	—	—		—		ND	—		—	—	—	
	1. Universidad de Monterrey (Nuevo León)	BL3									X	X				X	X	no
Mexico	2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Laboratorio Nacional de Máxima Seguridad Biológica para el Estudio de la Tuberculosis y Enfer- medades Emergentes (LNMSBETEE) (Tlalpan)	BL3	_	_	_	_	_	_	_	_	X	X	NN	NN	NN	X	X	no

	3.T 11 00 W 1 1 1								1 car (or Deer	aratioi							
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	3. Centro de Investigación en Tecnología y Diseno del Estado de Jalisco A.C. Dirección de Biotecnología Médica y Farmacéutica (Ja- lisco)	BL3									X	X				X	X	no
	4. Laboratorios de Diagnostico del Departmento de Medicinca Zootecnia de Cerdos, Facultad de Medicina Veterinaria y Zootecnia (Coyoacán)	BL3									X	X				_	_	_
	5. Instituto Nacional de Enfermedades Res- piratorias Ismael Cosío Villegas. Unidad de Investigación (Tlalpan)	BL3									X	X				X	X	no
	6. Instituto de Diagnóstico y Referencia Epidemiológicos "Dr. Manuel Martínez Báez". Dirección General de Epidemiología. Secretaría de Salud. (Álvaro Obreg)	BL3									X	X				X	X	no
	7. Servicio Nacional de Sanidad, Inocuidad y Calidad Agroalimentaria. Comisión México Estados Unidos para la prevención de la Fiebre Aftosa y otras enfermedades exóticas de la carinal de (Carinales)	BL3									X	X				X	X	no
	los animales (Cuajimalpa) 8. Laboratorio Estatal de Salud Pública del Estado de Sonora (Sonora)	BL3									X	X				X	X	no
	9. Universidad Nacional Autónoma de México. Instituto de Investigaciones Bi- omédicas (Coyoacán)	BL3									X	X				X	X	no
	10. Laboratorio Estatal de Salud Pública de Veracruz (Veracrus)	BL3									X	X				X	_	no
	11. Centro Nacional de Servicios de Diagnóstico en Salud (Pachuca de Sonto)	BL3									X	X				_		
Morocco	_		_					_			_	_			NN			
Myanmar	_	_	_	_	_	_	_	_	_	_	_	ND	_	ND	_	_	_	_

	NT 11 11 00 00 111 1 1 1								rear	or Deci	aramor	1						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	1. TNO Department of CBRN Protection (Rijswijk)	BL3							X	_	X	X	X	X	X	X	X	mostly
Netherlands	2. National Institute for Public Health and the Environment Rijksinstituut voor Volks- gezondheid en Milieu (Bilthoven)	BL3	_	_	_	_	_	_	X	X	X	X	X	X	X	X	X	no
New Ze- aland	National Centre for Biosecurity and Infectious Disease (Upper Hutt)	BL3+	X	X	_	X	X	X	X	X	X	X	X	X	X	X	X	no
Norway	Institute of Microbiology, Armed Forces Medical Services (Oslo)	BL3	_	X	_	X	NN	NN	NN	NN	NN	ND	ND	ND	ND	ND	ND	
	1. Laboratório de Bromatologia e Defensa Biológica (Lisbon)	BL3				X	X	X	X	X	X							partly
	2. Unidade de reposta a Emergências e Bio- preparação (Lisbon)	BL3				X		_		_								_
	3. Departamento de Doenças Infecciosas (Lisbon)	BL3				_	_	X	X	X	X							no
	4. Unidade de reposta a Emergências e Bio- preparação (Braga)	BL3					_	_										_
Portugal	5. Institutio Nacional de Investigação Agrária e Veterinária, Unit of Animal Health (Lisbon & Vila do Conde)	BL3	_	_	_	_	_	X	X	X	X	NN	NN	NN	NN	NN	NN	no
	6. Life and Health Sciences Research Institute (Braga)	BL3							X	X	X							_
	7. Instituto de Tecnologia Química e Bi- ológica (Lisbon)	BL3					_	_	_		X							no
	8. Departamento de Farmácia Galénica e Tecnologia Farmacêutica (Lisbon)	BL3								X	X							no
	9. Departamento de Microbiologia e Imunologia (Lisbon)	BL3				_	_	_	_	X	X							_
	10. Facultade de Ciências da Universidade de Lisboa (Lisbon)	BL3				_	_	_	_	_	_							no
Qatar	Nothing new to declare	_	_	_	_			ND	ND	_		_		_		_	_	



									I Cui		ururor	•						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
Republic of	1. National Center for Public Health (Chinsinau)	BL3					X	X	> 1> 1	> 1> 1	.	.		2.12.1		> 1> 1	> T> T	_
Moldova	2. Republican Center for Veterinary Diagnostics (Chinsinau)	BL3	_	_	_	_		X	NN	NN	NN	NN	_	NN	_	NN	NN	_
	1. Military Medical Research Center (Bucharest)	BL2+4	X				X	X	X	_	_	X	X	X	X	X	X	wholly
	2. National Society "Pasteur Institute" (Bucharest)	BL2	_				_	_	_	X	X	X	X	X	X	X	X	no
	3. Institute for Hygiene and Veterinary Public Health (Bucharest)	BL2	_				_	_	_	X	X	X	X	X	X	X	X	no
Romania	4. "Cantacuzino" National Medico—Military Institute of Research and Development (Bu-	BL2 ⁵	_	NN	NN	NN	_	X	_	_	X	X	X	X	X	X	X	no
	charest) 5. Institute for Diagnosis and Animal Health (Bucharest)	BL3	_				_	_	_		X	X	X	X	X	X	X	no
	6. Institute for Control of Veterinary Biological Products and Medicines (Bucharest)	BL2	X				_	_		_	X	X	X	X	X	X	X	_
	7. National Institute for Infectious Diseases "Matei Bals" (Bucharest)	BL36	_				_	_	_	_	_	_	_	_	X	X	X	no
Serbia	Nothing to declare	_	_	—				ND		ND	ND		ND	ND	ND	ND	ND	_
Slovakia	Nothing to declare	_		_	_	_	_		_	ND	_		_	ND	ND	NN	ND	
Slovenia ⁷	1. University of Ljubljana, Faculty of Medicine Institute of Microbiology and Immunology (Ljubljana)	BL3	_	_	_	_	_	_	_	NN	NN	NN	NN	NN	NN	ND	X	
	2. Ministry of Defence - mobile laboratory (Kranj)	BL3	_	_	_	_	_	_	_	_	_	_	_	_	_	_	X	



⁴ Biosafety level 3 is under construction (2021, p. 6).
⁵ Biosafety level 3 is not operational (2021, p. 9)
⁶ Biosafety level 3 is not fully operational, pending validation (2021, p. 7)
⁷ Slovenia has mistakenly ticked "nothing to declare" although in its CBM submission it declared three BS3 (2021, p.4), with no further information provided.

									rear	or Deci	laratioi	1						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	3. University of Ljubljana, Veterinary Faculty, National Veterinary Institute (Ljubljana)	BL3															X	
	1. Swedish Defence Research Agency Division of NBC Defence (Umea)	BL3	X	X	X	X	X	_	_	_	_	_	_	X	_	_	_	_
Sweden	2. High Containment Laboratory, Public Health Agency of Sweden (Solna)	BL4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no
	3. National Veterinary Institute (Uppsala)	BL3	X	X	X	X	X							X				
	1. Labor Spiez (Spiez)	BL3				X	X	X	X	X	X	X	X	X	X	X	X	partly
Switzerland	2. Institute of Virology and Immunology (Mittelhäusern)	BL3	NN	NN	NN	X	X	X	X	X	X	X	X	X	X	X	X	no
Switzenand	3. National Reference Center for Emerging Viral Infections (Geneva)	BL4	1111	1111	1111	X	X	X	X	X	X	X	X	X	X	X	X	no
	4. Institute of Medical Virology (Zurich)	BL4				_		—	—	X	X	X	X	X	X	X	X	no
Thailand	Nothing new to declare		_	_	_	NN	NN	NN	_	_	_	_		_	_	_		_
	1. Ankara University Biotechnology Institute (Ankara)	BL2					X	X										
	2. Refik Saydam National Public Health Agency (Ankara)	BL3					X											
Turkey	3. Bornova Veterinary Control and Research Institute (Ankara)	BL3	_	_	_	_	X	_	NN	NN	NN	NN	NN	NN	_	_	_	_
	4. Diagnosis of Poultry Disease Laboratory (Ankara)	BL3					X	_										
	5. Biosafety Level—3 Laboratory Institute (Ankara)	BL3					_	X										
Ukraine	1. Governmental Scientific Oversight Insti- tute for Biotechnology and Microorganism Culture Collection (Kiev)	_	_	_	_	_	X	X	_	_	_	_	_	X	_	_	_	_
	2. State institution "Institute of Microbiology and Immunology I.I. Mechnikov of the	_					X	X			X	X	X	X	X	X	X	partially



									1 car (or Deer	aratioi	ı						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	National Academy of Medical Sciences of																	
	Ukraine" (Kharkov)																	
	3. State institution "Institute of Epidemiol-																	
	ogy and Infectious Diseases named after	BL2					X	X			X	_	X	X	X	X	X	no
	L.V. Gromashevsky NAMS of Ukraine"																	
	(Kiev) 4. State institution "Ukrainian Research																	
	Anti—Plague Institute I.I. Mechnikov" of	BL3					X	X			X	X	X	X	X	X	X	no
	the Ministry of Health of Ukraine (Odessa)	220																110
	5. Central Sanitary Epidemiological Station	BL3																
	(Kiev)	DL3					X	X			_							_
	6. State institution "Lviv Research Institute	D																
	of Epidemiology and Hygiene of the Minis-	BL3					X	X			X	X	X	X	X	X	X	no
	try of Health of Ukraine" (Lviv) 7. National Scientific Center "Institute of																	
	Experimental and Clinical Veterinary Medi-	BL2						X			X	X	X	X	X	X	X	no
	cine" (Kharkov)	DL2						Α.			Λ	Α.	Λ	14	24	14	21	110
	8. Institute of Veterinary Medicine of the																	
	National Academy of Agrarian Sciences of						_	X			X	X	_	X	X	X	X	no
	Ukraine (Kiev)																	
	9. State institution "Center for Public Health																	
	of the Ministry of Health of Ukraine" — former State institution "Ukrainian Centre for	BL3																
	Disease Control and Monitoring of the Min-	DL3					_				X	X	X	X	X	X	X	no
	istry of Health of Ukraine" (Kiev)																	
	10. State Scientific Control Institute of Bio-																	
	technology and Microorganism Strains	BL2					_	_			X	X	X	X	X	X	X	no
	(Kiev)																	
	11. State Research Institute of Laboratory	DI O																
	Diagnostics and Veterinary and Sanitary Ex-	BL2					_				_		_	X	X	X	X	no
United	pertise (Kiev) 1. Defence Science and Technology Labora-																	
Kingdom	tory, Porton Down (Salisbury)	BL4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	yes
8	,, (-)/																	



									I Cai	JI DCCI	arauoi	1						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	2. Public Health England — Colindale (London)	BL4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no
	3. Public Health England — Porton (Salisbury)	BL4	X	X	X	X	X	X	_	X	X	X	X	X	X	X	X	no
	4. National Institute for Biological Standards and Control (Potters Bar)	BL4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no
	5. The Francis Crick Institute Containment 4 facility (London)	BL4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no
	6. The Pirbright Institute (Pirbright)	SAPO4							X	X	X	X	X	X	X	X	X	no^8
	7. Animal and Plant Health Agency (Addlestone)	SAPO4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no
	8. Institute for Animal Health, Pirbright Laboratory (Woking)	SAPO4	X	X	X	X	X	X										_
	9. Boehringer Ingelheim Animal Health UK Limited, former Merial Animal Health, Bio- logical Laboratory (Pirbright)	SAPO5	_	X	X	X	X	X	X	X	X	X	X	X	X	X	X	no
	10. Schering—Plough Animal Health (Ux-bridge)	SAPO4		X														_
	11. Biobest Secure Unit (Milton Bridge)	BL4	—	—	—	_		—	—	_	—		—	—		—	X	no
	1. Georgia State University — High Containment Core (Atlanta, GA)	BL4				X	X	X	X	X	X	X	X	X		X	X	partly
	2. The Betty Slick and Lewis J. Moorman, Jr. Laboratory Complex (San Antonio, TX)	BL4				X	X	X	X	X	X	X	X	X	X	X	X	partly
USA	3. Galveston National Laboratory (Galveston, TX)	BL4	_	_	_	X	X	X	X	X	X	X	X	X	X	X	X	partly
	4. Plum Island Animal Disease Center (Greenport, TX)	BL3				X	X											
	5. U.S. Army Medical Research Institute of Infectious Diseases (Fort Detrick, MD)	BL4				X	X	X	X	X	X	X	X	X	X	X	X	partly



 $^{^{\}rm 8}$ Partially funded by the US Defense Advanced Research Projects Agency.

									I car (JI 2001	urumor	•						
Country	Name and location of facilities declared in CBM Form A, Part 1	Cont. Level	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	MoD funded?
	6. National Biodefense Analysis and Countermeasures Center (Fort Detrick, MD)	BL4				_	_	X	X	X	X	X	X	X	X	X	_	no
	7. Integrated Research Facility at Rocky Mountain Laboratories (Hamilton, MT)	BL4						X	X	X	X	X	X	X	X	X		no
	8. Coordinating Center for Infectious Diseases (Atlanta, GA)	BL4				X			_									_
	9. CDC, Deputy Director for Infectious Diseases (Atlanta, GA)	BL4						X	X	X	X	X	X	X	X	X	X	no
	10. Integrated Research Facility at Fort Detrick — NIAID (Fort Detrick, MD)	BL4								X	X	X	X	X	X	X	X	no
	11. The Boston University National Emerging Infectious Diseases Laboratories — NEIDL (Boston)	BL4				_	_	_	_	_	_	_	_	X	X	X	X	no

CBM Form A, Part 2 (ii)

The following table summarizes the data declared in **CBM Form A, Part 2 (ii)** of the publicly available CBM submissions from 2021 and compares them with the information in publicly available CBMs from 2007 to 2021. The table indicates the overall funding for the biodefence programme as declared in CBM Form A, part 2 (ii), and lists the names and locations of biodefence facilities declared in CBM Form A, part 2 (iii), specifying the year(s) they were declared. Grey cells indicate that there was no CBM submission or that it was not made publicly available in the respective year. "ND" indicates that the state ticked the "Nothing to declare" box in Form 0. "NN" indicates that the state ticked the "Nothing new to declare" box in Form 0. "—" indicates that no data were provided.

Country			Y	ear of De	claration	ı — Tota	d funding	g in milli	on EUR d	leclared i	n Form A,	Part 2 (ii)9		
·	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Australia	1.5	1.6	1.7	1.7	2	2	2	1.7	1.7	2.1	2.1	2.3	2.2	1.8	2.5
Austria	_	_	0.01	0.03	0.05	0.03	0.02	0.09	0.09	0.09	0.02	0.09	0.63	5	5

⁹ National currencies were converted to Euros using the online service, http://www.finanzen.net/waehrungsrechner. 15 April of each respective year, the deadline for submitting the CBM to the UN is selected as the date for the currency conversion.



Belgium	_				0.6	1	0.3	0.3	0.4	0.2	0.3	0.26	0.24	0.27	0.35
Bulgaria	_	_	_	_	_	NN	NN	NN	NN	ND	ND	ND	NN	_	NN
Canada	_	_	_	_	6	6.6	9.3	9.6	6.5	6.6	6.3	4	3.1	2.4	1.9
Croatia			_		_	_	_	ND				ND	_	_	
Cyprus			_		_	_	_	_					NN	NN	NN
Czech Rep.	_	_	NN	_	_	NN	_	_	NN	NN	NN	NN	NN	NN	NN
Denmark	1.9	2	_	2.9	2.8	2.7	2.7	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
Ecuador		_	_		ND	_	_	_		<u>—</u>	<u>—</u>	<u>—</u>	_	_	
Estonia	_	_	_	ND	ND	_	_	_	ND	ND	ND	ND	ND	ND	ND
Finland			_		_	_	_	_					_	_	
Georgia			0.3	1.7	1.6	_	_	_					_	_	
Germany	11.7	11.4	11.2	9.9	9.6	15	16	14.6	15.4	18	17.4	17.3	18.5	17.6	20.9
Greece	_		_		ND	ND	ND	_					_	_	
Hungary	_		_		_		_	_					_	_	
Ireland	_		_		_		_	_				NN	NN	NN	NN
Japan			_		_	1.1	2.3	2.5	0.01	0.01	0.01	0.4	0.28	0.3	0.38
Latvia					_	_	_	NN			ND	ND	ND	ND	ND
Liechtenstein	NN	NN	NN	NN	NN	_	NN	NN					_	_	
Lithuania	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Luxembourg			_		_	ND	_	ND	ND	ND	ND	ND	ND	ND	ND
Madagascar	_	_	_	_	_	ND	_	_	_	_	_	_	_	_	_
Malaysia					ND	_	_	_					_	_	
Mauritius		_	_	_	_	_	_	_	_	ND			_	_	
Mexico		_	_	_	_	_	_	_	ND	ND	ND	ND	ND	ND	ND
Morocco	_	_	_	_	_	_	_	_		<u>—</u>	<u>—</u>	_	ND	_	

Myanmar										ND		ND			
Netherlands		_	_		_	_	1.2	1.2	1	1	1	3	3	3.6	3.6
New Zealand	ND	ND	_	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Norway	_	_	_	_	_	0.5	_	_	2	2.6	NN	NN	NN	2.6	1.7
Portugal	_	_	_	0.2	0.1	0.1	0.03	0.05	0.26	0.26	0.04	0.11	NN	0.23	0.24
Qatar	_	_	_	_	_	ND	ND	_	_	_	_	_	_	_	_
Republic of Moldova		_	_		_	NN	NN	0.03	NN	NN		0.03	_	0.03	0.03
Romania	_	_	NN	NN	_	0.01	0.01	ND	ND	ND	ND	ND	ND	ND	ND
Serbia	_	_	_	_	_	ND	_	ND	ND	_	ND	ND	ND	ND	ND
Slovakia	_	_	_		_	_	_	ND		_		ND	ND	ND	ND
Slovenia	_	_	_	_	_	_	_	ND	ND	ND	ND	ND	ND	ND	ND
Sweden	2.8	2.7	2.7	3.1	3.5	3.5	3.5	4.2	3.7	3.2	3	3.2	3.7	2.9	3.5
Switzerland	0.6	0.6	1	1.7	3.9	4.2	4.1	4.1	4.9	4.8	4.7	4.4	4.4	4.7	4.6
Thailand	_	_	_	NN	NN	NN	_	_	_	_	_	_	_	_	_
Turkey		_	_		2.3	NN	NN	1.7	ND	ND	ND	ND	_	_	_
Ukraine	_			_	ND	ND		_	ND	ND	ND	ND	ND	ND	ND
United Kingdom	75	77.6	65.7	53.6	57.8	62	60.1	59.1	69.4	66.5	58.2	52.2	45.9	52.3	49.6
	_			451.6	475	779	743	670	812.4	730.4	668.8	547.7	694	693	618

CBM Form A, Part 2 (iii)

The following table summarizes the data declared in **CBM Form A, Part 2 (iii)** of the publicly available CBM submissions from 2021 and compares them with the information in publicly available CBMs from 2007 to 2021. The table lists the names and locations of biodefence facilities declared in CBM Form A, part 2 (iii), specifying the year(s) they were declared. Grey cells indicate that there was no CBM submission or that it was not made publicly available in the respective year. "ND" indicates that states ticked the "Nothing to declare" box in Form 0. "NN" indicates that states ticked the "Nothing new to declare" box in Form 0 and provided no further information. "—" indicates that no data was provided or data was not



made publicly available (either on the ISU—website or by providing the Hamburg Research Group with the CBM) in the respective year. Cells with background colour indicate that data applies to all cells.

Country	Name and location of facilities declared															
	in CBM Form A, Part 2 (iii)	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Australia	Biological Defence Research, Land Division, Defence Science and Technology Group (Fishermans Bend)	X	X	X	X	X	X	X	x	x	X	X	X	X	X	X
Austria	Armament and Defence Technology Acency, Division NBC & Environmental Protection Technology (Vienna)	_	_	X	X	X	X	x	X	X	X	X	X	X	X	X
	 Centre de Technologies Moléculaires Appliquées — Laboratoires de la Défense (Brussels) 					X	X	x	X	X	X	X	X	X	X	x
	2. Centre de Technologies Moléculaire Appliquée — Mycologie (Louvain—La—Neuve)					_	_	_	X	x	X	X	X	_	_	_
Belgium	3. DLD Defense Laboratory Department (Vilvoorde Peutie)	_	_	_	_	X	X	X	X	X	X	X	X	_	_	_
	4. Research Laboratory for Vector Borne Disease (Brussels)					X	_	_	_	_	_	_	_	_	_	_
	5. UCL, Faculté des Sciences Agronomiques, Unité de microbiologie (Louvain—La—Neuve)					X	X	X	X	X	X	_		_		
.	1. National Center of Infectious and Parasitic Diseases, Ministry of Health of the Republic of Bulgaria (Sofia)	X	X		X	X	X	X	X	X						
Bulgaria	2. National Research Diagnostic Veterinary Institute, Bulgarian Food Safety Agency (BFSA) of the Republic of Bulgaria (Sofia)		_	_	_	_	_	_	_	X	ND	ND	ND	NN	_	NN
Canada	1. Defence Research and Development Canada — Suffield Research Centre (Medicine Hat, AB)					X	X	x	X	X	X	X	X	X	X	x
Canada	2. Defence Research and Development Canada (DRCD) — Valcartier Research Centre (Québec, QC)	_	_	_	_	X	X	x	X	X	X	X	X	X	X	X

Croatia ¹⁰	University Hospital for Infectious Diseases "Dr. Fran Mihaljevic", Central Diagnostic Laboratory (Zagreb)	_	_	_	_	_	_	_	ND	_	_	_	ND	_	Х	X
Cyprus	Nothing to declare	_		_	_	_		_	_			_	_	ND	NN	NN
	Central Military Health Institute, department Techonin (Techonin)	X	X			X	X	_								
	2. Central Military Health Institute, department Prague (Prague)					X	X	X								
Czech Rep.	3. Institute of Molecular Pathology (IMP) (Hradec Králové)	X	X	NN	ND	X	X	X	ND	ND	NN	ND	ND	ND	ND	NN
	4. Laboratory for Biological Monitoring and Protection (Milin)	X	X			X	X	_								
	5. Laboratory of Molecular Biology, GENERI BIOTECH s.r.o. (Hradec Kralove)	X	X			—		_								
Denmark	Center for Biosecurity and Bioprepardness (Copenhagen)	X	X	_	X	X	X	X	X	X	X	NN	X	X	X	X
Ecuador	Nothing to declare	_	_		_	ND		_	_			_	_	_	_	
Estonia	Nothing to declare	_	_		ND	ND		_	_	ND						
Finland	Center for Biothreat Preparedness (Helsinki)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	x
Georgia	1. National Center for Disease Control and Public Health (Tbilisi)	_	_	X	X	X	_	_	_	_	_	_	_	_	_	_
	2. Laboratory of Ministry of Agriculture of Georgia (Tbilisi)			_	X	X										
	1. CBRN Defence, Safety and Environ- mental Protection School (Sonthofen)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2. Bundeswehr Institute of Microbiology (Munich)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Germany	3. Bundeswehr Research Institute for Protective Technologies and NBC—Protection (Munster)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4. Central Institute of the Bundeswehr Medical Service (Kiel)	_	X	X	_	X	X	X	X	X	X	X	X	X	X	X

 $^{^{\}rm 10}$ Croatia ticked "nothing to declare" but reported a new facility.



	5. Centre for Biological Threats and Special Pathogens at the Robert Koch Institute (Berlin)		_	_	_	_	_	_	X	X	X	X	X	X	X	X
Greece	Nothing to declare	_				ND	ND	ND				_	_	_	_	
Hungary	Medical Centre of Hungarian Defence Forces (Budapest) Biosafety Laboratory (Budapest)	_	_	_	_	_	_	_	X	X	_	_	_	_	_	_
Ireland	"Ireland does not have a national biological defence R&D programme"	_								ND	ND	ND	NN	NN	NN	NN
Japan	 Military Medicine Research Unit, Test & Evalutation Command (Tokyo) National Defense Medical College (Saitama) 	—	_	_	_	_	x —	NN	NN	NN	NN	NN	x	x	x	X
Latvia	Riga East University Hospital, Latvian Centre of Infectious Diseases, National Microbiology Reference laboratory (Riga)		—	_	_	X	X	NN	X	X	X	X	X	NN	NN	NN
Liechtenstein	Nothing new to declare	NN	NN	NN	NN	NN		NN	NN			_				_
Lithuania	Nothing to declare	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Luxembourg	"Luxembourg does not have national research and development programs for biological defense on the territory"	_	_	_	_	_	ND	_	ND	ND	ND	ND	ND	ND	ND	ND
Madagascar	Nothing to declare						ND									
Malaysia	Nothing to declare	_	_	_	_	ND	_	_	_	_	_	_		_		
Mauritius	Nothing to declare		_					_			ND	_				
Mexico	Nothing to declare	_	_	_	_	_	_	_	_	ND	ND	ND	ND	ND	ND	ND
Morocco	Nothing to declare	_	_	_	_	_	_	_	_	_	_	_		_		
Myanmar	Nothing to declare	_	_	_	_	_	_	_	_	_	ND	_	_	_	_	
Netherlands	TNO Prins Maurits Building; Department of CBRN Protection (Rijswijk)		_	_	_	_	_	X	X	X	X	X	X	X	X	X
New Zealand	Nothing to declare	ND	ND		ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Norway	Institute of Microbiology, FML (Kjeller) Norwegian Defence Research Establishmend, FFI (Kjeller)	_	x 	_	X 	NN	NN	NN	NN	x x	NN	NN	NN	NN	NN	NN



	3. Norwegian Institute of Public Health, FHI (Oslo)				_					X						
Portugal	Laboratório de Bromatologia e Defensa Bi- ológica (Lisbon)	_	_	_	X	X	X	X	X	X	X	X	NN	NN	NN	NN
Qatar	Nothing to declare	_					ND	ND						_		
Republic of Moldova	The National Center of Public Health (Chisinau)	_	_	_	_	X	NN	X	X	NN	NN	_	ND	_	_	
Romania	Military Medical Research Center (Bucharest)	_	X	NN	NN	X	X	X	ND							
Serbia	Nothing to declare						ND		ND							
Slovakia	Nothing to declare	_	_						ND				ND	ND	ND	ND
Slovenia ¹¹	 University of Ljubljana, Veterinary Faculty, National Veterinary Institute (Ljubljana) University of Ljubljana, Medical Faculty, Institute of microbiology and immunology (Ljubljana) 	_	_	_	_	_	_	_	_	_	_	_	_	_	_	x x
Sweden	1. Swedish Defence Research Agency (Umea)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2. National Veterinary Institute (Uppsala)		X					X	X	X	X	X	X	X	X	X
	1. Spiez Laboratory — Swiss NBC Defence Establishment (Spiez)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2. Institute of Virology and Immunology (Mittelhäusern)				X	X	X	X	X	X	X	X	X	X	X	X
C 1 1 1	3. National Reference Center for Emerging Viral Infections (Geneva)	_	_	_	X	X	X	X	X	X	X	X	X	X	X	X
Switzerland	4. National Reference Center for Anthrax (Bern)	_	_	_	X	X	X	X	X	X	X	_	_	_	_	_
	5. Bacteriological Laboratory (Geneva)	_			X	X	X	X	X	X	X	X	X	X	X	X
	6. Virological Laboratory — National Reference Center for Emerging Viral Infections (Geneva)				X	X	X	X	X	X	X	X	X			
	7. Diagnostic Laboratories of the Institute of Microbiology (Lausanne)			_	X	X	X	X	X	X	X	X	X	X	X	X

¹¹ Slovenia has mistakenly ticked "nothing to declare" although in its CBM submission it declared three BS3 (2021, p.7), with no further information provided.



	8. Spiez Laboratory — National Reference Center (Spiez)		_	_	X	X	X	X	X	X	X	X	X	_	_	_
	9. Department of Medical Micobiology (Luzern)		_		X	X	X	X	X	X	X	X	X	X	X	X
	10. Institute of Medical Microbiology (Zurich)	_	_	_	X	X	X	X	X	X	X	X	X	X	X	X
	11. Institute for Medical Virology (Zurich)				X	X	X	X	X	X	X	X	X	X	X	X
	12. Cantonal Laboratory of Basel—Stadt (Basel)	_		_	X	X	X	X	X	X	X	X	X	X	X	X
	13. Laboratory of Applied Microbiology (Bellinzona)			_	X	X	X	X	X	X	X	X	X	X	X	X
Thailand	Nothing new to declare				NN	NN	NN					_	_	_		
	1. DIDC (Ankara)					X										
Turkey	2. Refik Saydam National Public Health Agency (Ankara)		_	_	_	X	NN	NN	NN	ND	ND	ND	ND	_	_	
Ukraine	State Scientific and Control Institute for Biotechnology and Microorganism Strains (Kiev)	_	_	_	_	ND	ND	_	_	ND	ND	ND	ND	ND	ND	X
United King- dom	Defence Science and Technology Laboratory (Porton Down Salisbury)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	1. Plum Island Animal Disease Center (Orient Point, NY)				X	Х	Х	X	X	X	X	X	X	X	X	X
	2. Tyndall Air Force Base 1, Research Road (Tyndall, FL) — closed in 2013				X	X	X	X	_	_	_	_	_	_	_	_
	3. Tyndall Air Force Base 2, Barnes Drive (Tyndall, FL)				x	X	X	X	_	_	_	_	_	_		_
	4. Lothar Salomon Test Facility (Dugway, UT)				X	X	X	X	X	X	X	X	X	X	X	X
USA	5. U.S. Army Combat Capabilities Development Command Chemical and Biological Center, former U.S. Army Edgewood Chemical and Biological Center (Aberdeen, MD)	_	<u> </u>	_	X	X	X	X	X	X	X	X	X	X	X	X
	6. U.S. Army Medical Research Institute of Chemical Defense (Aberdeen, MD)				X	X	X	X	X	X	X	X	X	X	X	X
	7. U.S. Army Medical Research Institute of Infectious Diseases (Fort Detrick, MD)				X	X	X	X	X	X	X	X	X	X	X	X



8. Walter Reed Army Institute of Research	
(Silver Spring, MD)	
9. Battelle Biomedical Research Center	
(West Jefferson, OH)	
10. Naval Surface Warfare Center—	
Dahlgren Division Chemical, Biological,	
Radiological Defense Laboratory	
(Dahlgren, VA)	
11. Naval Research Laboratory (Washing-	
ton, DC)	
12. Naval Medical Research Center (Fort	
Detrick, MD)	
13. Brookhaven National Laboratory (Up-	
ton, NY)	
14. Idaho National Laboratory (Idaho Falls,	
ID)	
15. Los Alamos National Laboratory (Los	
Alamos, NM)	
16. Lawrence Livermore National Labora-	
tory (Livermore, CA)	
17. Oak Ridge National Laboratory (Oak	
Ridge, TN)	
18. Pacific Northwest National Laboratory	
(Richland & Sequim, WA)	
19. Sandia National Laboratories (Albu-	
querque, NM and Livermore, CA)	
20. C.W. Bill Young Center for Biodefense	
and Emerging Infectious Diseases (Be-	
thesda, MD)	
21. Integrated Research Facility at Rocky	
Mountain Laboratories (Hamilton, MT)	
22. Dale and Betty Bumpers Vaccine Re-	
search Center (Bethesda, MD)	
23. CDC Mass Spectrometry Toxin Labor-	
atory — since 2012 within No. 28 (Atlanta,	
GA)	
24. Foreign Disease—Weed Science Re-	
search Unit (Fort Detrick, MD)	
ocaren em (1 on Demen, 111)	

X	X	X		_				_		_	
X	X	_		_	_	_	_	_	_	_	_
X	X	X	X	X	X	X	X	X	X	X	X
X	X	X	X	X	X	X	X	X	X	X	X
X	X	X	X	X	x	X	X	X	X	X	X
X	X	X	X	X	X	X	X	X		_	_
X	X	X	X			_				_	
X	X	X	X	X	x	X	X	X	X	X	X
X	X	X	X	X	X	X	X	X	X	X	X
X					_	_	_				
X	X	X	X	X	X	X	X	X	X	X	X
X	X	X	X	X	X	X	X	X	X	X	X
X	X	X	X	X	X	X	X	X	X	X	X
X	X	X	X	X	X	X	X	X	X	X	X
X	X	X	X	X	X	X	X	X	X	X	X
X	X			_	_	_	_	_	_	_	_
X	X	X	X	X	X	X	X	X	X	X	X



25. National Animal Disease Center (Ames,	X	X	X	X	X	X	X
IA)							
26. Southeast Poultry Research Laboratory	X	X	X	X	X	X	X
(Athens, GA)							
27. National Biodefense Analysis and							
Countermeasures Center (Fort Detrick,		X	X	X	X	X	X
MD)							
28. Centers for Disease Control and Pre-							
vention, National Center for Environmen-			X	X	X	X	X
tal Health, Division of Laboratory Services							
(Buford Highway, Atlanta, GA)							
29. Centers for Disease Control and Pre-							
vention, Deputy Director for Infectious	X	X		X		\mathbf{X}	X
Diseases (Clifton Road, Atlanta, GA)							
30. CDC, DDID, National Center for							
Emerging and Zoonotic Infectious Dis-	v	v	v	v	v	v	v
eases, Division of Vector Borne Diseases	X	X	X	X	X	X	X
(Fort Collins, CO)							
31. Lawrence Berkeley National Laboratory			37	37			
(Berkeley, CA)	_	_	X	X			_
32. Air Force Research Laboratory							
(Wright—Patterson Air Force Base, OH)	_	_		X	X		_
33. US Army Natick Soldier Research De-							
velopment and Engineering Center (Natick,							
MA)							
34. Integrated Research Facility at Fort							
Detrick (Fort Detrick, MD)					X	X	X
35. Food and Drug Administration, in-							
cludes the Center for Biologics Evaluation							
and Research and the Center for Drug							
Evaluation and Research (Silver Spring,							
MD)							
36. Argonne National Laboratory, develop-							
ment project in 2019 (Lemont, IL)							_
37. Food and Drug Administration College							
Park Campus (College Park, MD)							
38. Food and Drug Administration Moffett							
Campus (Bedford Park, IL)							
1 (



X

 \mathbf{X}

X

X

X

X

X

 \mathbf{X}

 \mathbf{X}

X

X

 \mathbf{X}

 \mathbf{X}

 \mathbf{X}

X

 \mathbf{X}

 \mathbf{X}

 \mathbf{X}

X

X

 \mathbf{X}

X

X

X

 \mathbf{X}

 \mathbf{X}

 \mathbf{X}

X

X

 \mathbf{X}

 \mathbf{X}

 \mathbf{X}

X

X

 \mathbf{X}

 \mathbf{X}

 \mathbf{X}

 \mathbf{X}

X

 \mathbf{X}

 \mathbf{X}

 \mathbf{X}

X

 \mathbf{X}

 \mathbf{X}

 \mathbf{X}

X

 \mathbf{X}

X

Floral and Nursery Plants Research, Beltsville Agricultural Research Center (Beltsville, MD)

CBM Form G

The following table summarizes the data declared in **CBM Form G** of the publicly available CBM submissions from 2020 and compares them with the information in publicly available CBMs from 2007 to 2019. It provides the names and locations of vaccine production facilities declared in CBM Form G, the year(s) they were declared, and the diseases against which vaccines were produced. ND" indicates that states ticked the "Nothing to declare" box in Form 0. "NN" indicates that states ticked the "Nothing new to declare" box in Form 0 and provided no further information. "—" indicates that no data was provided or data was not made publicly available (either on the ISU—website or by providing the Hamburg Research Group with the CBM) in the respective year. Cells with background colour indicate that data applies to all cells.

	Name and location of vac-	Cat. A	Other							Year	of Decla	ıration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	1. Seqirus (Australia) Pty Ltd																	
	(Parkville and Broadmeadows,	no	yes	X	X	X	X								X	X	X	X
	VIC)																	
	2. Queensland Institute of Medical Research (Herston	no	MOC		X	v	X											
	Roead)	110	yes		Λ	X	Α	NN	NN	NN	NN	NN	NN	NN				
1100014114	3. Ludwig Institute for Cancer							- 1. 1	- 1- 1	- 1 1	1,11,	1111	1,11,	- 1- 1				
	Research, Austin Hospital	no	yes		\mathbf{X}	X	X											
	(Heidelberg, VIC)																	
	4. GlaxoSmithKline Australia	no	yes												X	X	X	X
Austria	Pty Ltd (VIC)		, 00															
	Nothing to declare	n.a.	n.a.			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	1. GlaxoSmithKline Biologi-	n.a.	n.a.	_	_	_	_	X	X	X	X	X	X	X	X	_	_	
	cals S.A (Rixensart)																	

¹² As designated by the Centers for Disease Control and Prevention (CDC) in the USA.



⁷ The list of vaccines is removed in the public version of the CBM.

	Name and location of vac-	Cat. A	Other							Year	of Decla	ration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Bel- gium ¹³	2. Pfizer Animal Health (Louvain—la—Neuve)	n.a.	n.a.					X	_	_	_	_	_	_	_	_	_	
	1. BulBio—NCIPD Ltd (Sofia)	n.a.	n.a.	X	X		X	X	X	X								
Bulgaria	2. National Diagnostic and Research Veterinary Medical Institute (Sofia)	n.a.	n.a.	_	_	_	X	_	_	_	NN	NN	NN	NN	NN	NN	_	NN
	1. ID Biomedical Corporation of Quebec (GlaxoSmithKline Inc.) (Quebec City, QC)	n.a.	yes					_		X	X	X	X	X	X	X	X	X
	2. Sanofi Pasteur Limited (Toronto, ON)	n.a.	yes					_		X	X	X	X	X	X	X	X	X
	3. Medicago (Quebec City, QC)	n.a.	yes					_		_	_	X	X	X	X	X	X	X
	4. Immunovaccine (Halifax, NS)	An- thrax	yes					_		_		X	X	X	X	X	X	X
	5. Artemis Technologies Inc., No. 50 (Guelph, ON)	no	yes					X		X	X	X	X	X	X	X	X	X
Canada	6. Bioniche Life Sciences Inc., No. 8 (Belleville)	no	yes	_	_	_	_	X	NN	X	X	_	_	_	_	_	_	_
	7. Biovet Inc., No. 49 (Saint—Hyacinthe, QC) 8. Gallant Custom Laborato-	no	yes					X		X	X	X	X	X	X	X	X	X
	ries Inc., No. 45 (Cambridge, ON)	no	yes					X		X	X	X	X	X	X	X	X	X
	9. Elanco Canada Limited, No. 40 — former Novartis Animal Health Canada Inc. (Mississauga, ON) 10. Novartis Animal Health	no	yes					X		X	X	X	X	_	_	_	_	_
	Canada Inc. (Mississauga, ON)	no	yes					_		_	_	_	X	X	X	_	_	_

	Name and location of vac-	Cat. A	Other							Year o	of Decla	ration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	11. Elanco Canada Limited — Aqua Health, No. 40 — former Novartis — Aqua Health (Charlottetown (PEI) and Victoria (PEI))	no	yes					X		X	X	X	X	X	X	X	X	X
	12. Nutratech Inc., No. 58 (Winnipeg, MB)	no	yes					X		X	X	X				X	X	X
	13. Saskatoon Colostrum Co. Ltd., No. 44 (Saskatoon, SK)	no	yes					X		X	X	X	X	X	X	X	X	X
	14. Vacci—Vet Inc., No. 59 (Saint—Hyacinthe, QC) 15. Ceva Animal Health Inc.,	n.a.	yes								X					X	X	X
	No. 23 — former Vetech Laboratories Inc. (Guelph, ON)	no	yes					X		X	X	X	X	X	X	X	X	X
	16. Biovet Inc., No. 59 (Saint—Hyacinthe, QC)	no	yes									X	X	X	X			_
	17. InventVac (Vancouver, BC)	no	yes												X	X	X	X
	18. National Research Council of Canada (Ottawa, ON)	no	yes							_	_	_	_	_	X	X	X	X
	19. Prevtec Microbia Inc., No.60 (Saint—Hyacinthe, QC)20. Centre for Aquaculture	no	yes												X	X		
	Technologies Canada, No. 61 (Souris, PEI)	no	yes													X	X	X
	21. Pfizer Animal Health, No.4 (Saanichton)	no	yes					X		X								_
	22. Saskatchewan Research Council, No. 57 (Saskatoon)	no	yes					X		X					_			
	23. Vetcovac Ltée., No. 48 (Saint—Hyacinthe, QC)	no	yes					X		_	_	_	_	_	_	_	_	
	24. Intervet Canada Corp., No. 51 (Kirkland)	no	yes					X		_	_		_	_	_	_	_	_



	Name and location of vac-	Cat. A	Other							Year	of Decla	ıration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	25. Vétoquinol N.A. Inc., No. 34 (Lavaltrie)	no	yes					X		_	_	_	_	_	_	_	_	_
Croatia	Institute of Immunology	no	yes								X				X			ND
Cyprus	Nothing to declare			_	_			ND	ND	_						ND	ND	NN
	1. Baxter BioScience s.r.o (Kostolec nad Černými Lesy)	no	yes	X				X					_					
	2. SEVAPHARMA a.s. (Hostivar)	no	yes	X				X					X					
Czech	3. Bioveta, a.s. (Ivanovice na Hané)	An- thrax	yes	X	NN	NN	NN	X	NN	NN	NN	NN	X	NN	NN	NN	NN	NN
Republic	4. DYNTEC, spol. s.r.o. (Terezín)	no	yes	X	1111	1111	1,1,	X	1,1,	1111	1111	1,11,	X	2,12,	1111	2,12,	1,1,	1,1,
	5. BIOPHARM, Research Institute of Biopharmacy and Veterinary Drugs (Jíluvé u Prahy)	no	yes	X				X					X					
	1. Statens Serum Institute (Copenhagen)	no	yes	X	X			X						_	_			NN
Den- mark	2. Bavarian Nordic A—S (Kvistgaard)	Small- pox	yes	X	X	_	NN	X	NN	NN	NN	NN	X	X	X	NN	NN	
	3. AJ Vaccines (Copenhagen)	no	yes	_	_			_					X	X	X			
Ecuador	Nothing to declare							ND	—				—	—				
Estonia	Nothing to declare ¹⁴	_	_		_	_	ND	ND	_	_	_	ND	ND	ND	ND	ND	ND	ND
Finland	Nothing to declare ¹⁵		_	NN	NN	NN	NN	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Georgia	Nothing to declare	_	_			ND	ND	ND									_	
Ger- many	GlaxoSmithKline Vaccines former Novartis Vaccines	Botu- lism	yes	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

 $^{^{14}}$ There are no vaccine producing facilities in Estonia (2021, p. 6). 15 There are no vaccine producing facilities in Finland (2021, p. 18).



	Name and location of vac-	Cat. A	Other							Year	of Decla	aration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	and Diagnostix GmbH & Co. KG (Marburg) 2. GlaxoSmithKline Biologi- cals (Branch of SB Pharma	no	yes	Х	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	GmbH & Co KG) (Dresden)		yes	Λ	Λ	Λ	Λ	Λ	Λ	Λ	Λ	Λ	Λ	Λ	Λ	Λ	Λ	Λ
	3. IDT Biologika GmBH (Dessau—Rosslau)	Small- pox	yes	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4. Bavaria Nordic GmbH (Berlin): relocated to denmark (2014)	Small- pox	yes	_	_	_	X	X	X	X	_	_	_	_	_	_	_	_
	5. Dynavax GmbH — former Rhein Biotech GmbH (Düs- seldorf)	no	yes	_	_	_	X	X	X	X	X	X	X	X	X	X	X	X
	6. Vibalogics GmbH (Cuxhaven)	no	yes						X	X	X	X	X	X	X	X	X	X
	7. Burgwedel Biotech GmbH, MSD Group (Burgwedel)	Ebola	yes		_			_		_		_	_		X	X	X	X
	8. CureVac AG (Tübingen)	no	yes							_							X	X
	9. BioNTech Innovative Man- ufacturing Services GmbH	Ebola, Mar- burg, Lassa	yes	_	_	_	_	_	_	_	_	_	_	_	_	_	X	X
	10. Rentschler Biopharma SE (Laupheim)	yes ¹⁶	yes							_		_	_	_				X
Greece	Nothing to declare	_	_	_	_			ND	ND	ND		_	_	_	_	_	_	
	1. Omninvest Ltd. (Budapest)	no	yes								X	X						
Hungary	2. GlaxoSmithKline Biological Kft. (Budapest)	no	yes	_	_	_	_	_	_	_	_	X	_	_	_	_	_	_
Ireland	1. Elanco Laboratories (Sligo)	no	yes	X	X	X	X	X	_	_	X	X						

¹⁶ Tuberculosis vaccine (recombinant and non- recombinant). Smallpox vaccine (recombinant), Bordetella vaccine, HIV vaccine (recombinant), Zika vaccine (recombinant), Typhus vaccine, RSV, Newcastle Disease Virus (Drug Substance, recombinant), Influenza A (PR8 vaccine), VSV vaccine (recombinant), HSV-1 vaccine (recombinant), CoVid vaccine (recombinant).



	Name and location of vac-	Cat. A	Other							Year o	of Decla	ıration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	2. MSD International GmbH (Carlow)	no	yes								X	X	X	X				
	3. MSD International GmbH — former Schering—Plough (Brinny)	no	no ¹⁷	_	_	_	_				X	X	X	X	NN	NN	NN	NN
	4. Pfizer Ireland Pharmaceuticals (Dublin)	no	yes	_	_	_	_	_			X	X	X	X				
	1. Denka Seiken Co., Ltd (To- kyo)	no	yes						X	X		X		X			X	X
	2. Daiichi Sankyo Biotech Co., Ltd (Saitama)	no	yes						X	X		X		X			X	X
	3. Takeda Pharmaceutical Co.,Ltd (Osaka)4. The Research Foundation	no	yes						X	X		X		X			X	X
Japan	for Microbial Diseases of Osaka University (Osaka) 5. KM Biologics Co., Ltd	no	yes	_	_	_	_	_	X	X	NN	X	NN	X	NN	NN	X	X
	emerged from The Chemo— Sero—Therapeutic Research Institute (Kumamoto)	no	yes						X	X		X		X			X	X
	6. Japan BCG Laboratory (Tokyo)	no	yes						X	X		X		X			X	X
	7. Japan Poliomyelitis Research Institute (Tokyo)	no	yes						X	X		X						
Latvia	Nothing to declare	—				ND			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Liech- tenstein	Nothing new to declare	_	_	NN	NN	NN	NN	NN	_	NN	NN	_	_	_	_	_	_	_
Lithua- nia	Nothing new to declare ¹⁸	_	_	NN	NN	NN	NN	NN	NN	NN	NN	NN						



 $^{^{17}}$ The site holds a manufacturer's authorization for medical products for human use. None of these is a vaccine. 18 No vaccines are produced in Lithuania (2021, p. 13).

	Name and location of vac-	Cat. A	Other							Year	of Decla	aration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Luxem- bourg	Nothing to declare	_	_	_	_	_	_	_	ND	_	_	ND	ND	ND	ND	ND	ND	ND
Mada- gascar	_		_	_			—			_					—			
Malaysia	Institute of Veterinary Services (Putrajaya)	no	yes		_		_	X							_		_	
Mauri- tius	_	_	_	_	_	_	_	_	_	_	_	_	ND	_	_	_	_	_
	1. Centro de Investigación y Estudios Avanzados en Salud Animal, Universidad Autónoma del Estado de México (Toluca)	no	yes									X	_		_			_
Mexico	2. Laboratorios de Biológicos y Reactivos de México S.A de C.V. (Colonia Popotla and Colonia Santo Tomás) 3. Productora Nacional De	no	yes	_	_	_	_	_	_	_	_	X	X	NN	X	NN	NN	X
	Biológicos Veterinarios (Colo- nia Lomas Altas)	no	yes									_	_		X			X
Моново	1. Société de Productions Bi- ologiques et Pharmaceutiques Vétérinaires BIOPHARMA (Rabat)	Botu- lism	yes													X		
Morocco	2. M.C.I. SANTE ANIMALE (Mohammedia)	Botu- lism, An- thrax	yes	_	_	_	_	_	_	_	_	_	_	_	_	X	_	_
Myan-	1. Vaccine Research Centre, Department of Medical Re- search (Yangon)	no	yes		_	_	_	_	_	_	_	_	X		X	_	_	
mar	2. Vaccine Production Division, LBVD (Yangon)	An- thrax	yes										X		X			



	Name and location of vac-	Cat. A	Other							Year	of Decla	aration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	1. Wageningen Bioveterinary Research — former Central Veterinary Institute (Lelystad)	no	yes							X	X	X	X	X				X
	2. Intervet International B.V.— MSD Animal Health (Boxmeer)	no	yes							X	X	X	X	X	X	X	X	X
	3. Nederlands Vaccin Instituut (Bilthoven)	no	yes							X	_	_	_	_	_	_	_	
	4. WWY—WWP (Weesp)	no	yes							X	X	X	X	X	X	X	X	X
Nether- lands	5. Boehringer Ingelheim Animal Health Operation — former Merial Lelystad (Lelystad)6. Janssen Vaccines & Preven-		yes	_	_	_	_	_	_	X	X	X	X	X	X	X	X	X
	tion — former Janssen—Crucell Holland B.V. (Leiden)	yes ¹⁹	yes							X	X	X	X	X	X	X	X	X
	7. Erasmus Medical Center (Rotterdam)	yes ²⁰	yes							_	X	X	X	X	X	X	X	X
	8. Bilthoven Biologicals B.V. (Bilthoven) 9. Wacker Biotech B.V. —	no	yes							_	X	X	X	X	X	X	X	X
	former SynCo Bio Partners B.V. (Amsterdam)	no	yes							_	_	_	_	X	X	X	X	X
	10. Patheon Biologics (Gro- ningen)	no	yes							_	X	X	X	X	X	X		X
New Zealand	Nothing to declare	_	_	ND	ND	_	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	1. Pharmaq (Overhalla)	no	yes		X		X	X	X	X	X							
Norway	2. The National Veterinary Institute (Oslo)	no	yes	_	X	_	X	X	X	X	X	NN	NN	NN	NN	NN	NN	NN



¹⁹ Viral diseases: Ebola, Margburg, Zika, RSV, HIV, HPV, Influenza, SARS- CoV-2. Bacterial infectious diseases: ExPEC (E. coli) and MRSA (S. aureus).
20 Zoonotic viruses such as Ebola, Marburg, Crimean Congo, Hanta, SARS-coronaviruses, Avian Influenza. Arboviruses such as Denque, West Nile, Japanese Encephalitis, Rift Valley, Zika Respirat

	Name and location of vac-	Cat. A	Other							Year o	of Decla	ration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	3. The Norwegian Institute of Public Health (Nydalen)	no	yes		X		X	X	X	X	X							
Portugal	Genibet Biopharmaceuticals (Oeiras)	no	yes		_	_	ND	X	X	ND	ND	NN	NN	ND	NN	NN	NN	NN
Qatar	Nothing to declare	_	_					_	ND	ND								
Republic of Mol- dova	Nothing to declare ²¹	_		_	_	_	_	ND	ND	ND	ND	ND	ND	_	_	_	ND	ND
	1. The "Cantacuzino" National Medico—Military Institute for Research and Development (Bucharest)	no	yes	_	_	_	X		X	X	X	X	X	X	X	X	X	X
Romania	2. SC Pasteur — Filiala Filipesto Srl, working point Bucharest — former National Society "Pasteur Institute" S.A. (Bucharest)	no	yes	X	X	X	_	NN	X	X	X	X	X	X	X	X	X	x
	3. S.C. Pasteur Filiala Filipeti S.R.L (Prahova)	no	yes	_	_	_	_			X	X	_	_	_	_		_	_
	4. ROMVAC COMPANY S.A. (Voluntari)	An- thrax	yes	_		_	_			X	X	X	X	X	_	X	X	X
Serbia	Institute of Immunology and Virology "Torlak" (Belgrad)	no	yes						X		X	X		X	X	X	X	X
Slovakia	Nothing to declare			_	_	_	_	_	_	_	ND	ND			ND	ND	ND	ND
Slovenia	Nothing to declare		_	_	_	_	_	_	_	_	ND	ND	ND	ND	ND	ND	ND	ND
Sweden	1. Valneva Sweden AB — former Crucell Sweden AB — former SBL Vaccin AB, Solna (Stockholm)	no	yes	X	X	X	NN	NN	X	NN	X	NN	NN	NN	NN	NN	NN	NN

²¹ Currently there are no human vaccines manufactured and licensed in the Republic of Moldova (2021, p. 9).



	Name and location of vac-	Cat. A	Other							Year o	of Decla	ration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	2. UniTech Biopharma (Matfors)	no	yes	X	X	X			_		_							
	3. Cobra Biopharma (Matfors)	no	yes						X									
	1. Janssen Vaccines, Branch of Cilag International GmbH — former Crucell Switzerland	yes ²²	yes	_			X	X	X	X	X		X	X	X	X	X	X
Switzer-	AG (Bern) 2. Cytos Biotechnology AG (Schlieren)	no	yes	_	_	_	X	X	X	X	_		_	_	_	_	_	_
land	3. Pevion Biotech Ltd. (Ittingen)	no	yes	_	_	_	X	X	X	X	_	_	_	_	_	_	_	_
	4. EmergentBiosolutions Berna GmbH — former PaxVax Berna GmbH — former Crucell Switzerland AG (Thörishaus)	no	yes	_	_	_	X	X	X	X	X	X	X	X	X	X	X	X
	Lonza AG (Lonzastrasse)	no	no															X
	1. The Government Pharmaceutical Organisation (Bangkok)	no	yes				X	X	X									
	2. Merieux Biological Products Co., Ltd. (Chachoengsao)	no	yes				_	_	X									
Thailand	3. Queen Saovabha Memorial Institute (Bangkok)	no	yes	_	_	_			X	_	_	_	_	_	_	_	_	
Thailand	4. BioNet—Asia Co., Ltd. (Bangkok)	no	yes				_	_	X									
	5. Bureau of Veterinary, De- partment of Livestock Devel- opment (Nakhon Ratchsas- ima)	An- thrax	yes				_	_	X									



²² Disease targeted: Ebola virus disease - Name of vaccine: Ad26.ZEBOV (CBM 2021, p. 80).

	Name and location of vac-	Cat. A	Other							Year o	of Decla	ration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	Konya Veterinary Control and Research Institute (Meram—Konya) Ministry of Food Agricul-	no	yes					X			—							
	ture and Livestock — Veterinary Control Institute — former Pendik Veterinary Control and Research Institute (Istanbul)	no	yes					X			X	X	X	X	X			
	3. Ministry of Food Agriculture and Livestock — Veterinary Control and Central Research Institute — former Anthrax Vaccine Production Laboratory & Production of Tuberculin and Mallein Laboratory (Aphara)	An- thrax	no					X	NN	NN	X	X	X	X	X			
	boratory (Ankara) 4. Ministry of Food Agriculture and Livestock — Foot and Mouth Disease Institute (Ankara)	no	yes	_	_	_	_	_	NN	NN	X	X	X	X	X	_	_	_
	6. Veterinary Control Institute (Samsun) 7. VETAL Animal Health	no	yes								X	X	_	_	_			
	Products Company (Adi- yaman)	no	yes								X	X	_	X	X			
	8. DOLLVET Veterinary Vaccine, Medicine and Biological Materials Production Company (Sanliurfa)	no	yes					_			X	X	_	X	X			
	9. ATAFEN Veterinary Materials Production Company (Ismir)	no	yes								X	X	_	X	X			

	Name and location of vac-	Cat. A	Other							Year o	of Decla	ration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	10. AKUAKIM Medical, Chemical, Pharmaceutical, Feed Additives and Water Products Industry and Trade Company (Manisa)	no	yes					_			X	X	—	—	—			
	1. Sumy Biofactory (Sumy)	An- thrax	yes					X	X			X	X	X	X	X		
	2. Biofabrika Dnepropetrovsk (Dnepropetrovsk)	no	yes					X	X									
	3. Kharkov Biofactory (Kharkov)	no	yes					X	X			X	X	X	X	X		
	4. Kherson Biofactory (Kherson)	An- thrax	yes					X	X			X	X	X	X	X		
	5. Novogaleshchinsky Biofactory (Kiev)	no	yes					X	X			X		_	_	_		
	6. LLC "Ukrvetpromsnab" (Brovary)	no	yes					X	X			X	X	X	X	X		
	7. Corporation "Ukr- vetpromsnab" (Kiev)	no	yes					X	X			_	_	_	_	_		
Ukraine	8. Scientific Center "Institute for Experimental and Clinical Veterinary Medicine" (Khar- kov)	no	yes	_	_	_	_	X	X	_	_	X	_	_	_	_	NN	NN
	9. Institute of Veterinary Medicine of the National Academy of Agrarian Science of Ukraine (Kiev)	no	yes					X	X			X	_	_	_	_		
	10. PJSC "PHARMSTANDART BIO- LEC " (Kharkov)	no	yes					X				X	X	X	X			
	11. LLC "PHARMEX GROUP" (Shevchenko)	no	yes					_	_			_	X	X	X	_		
	12. TOV "Pharma Life" (Lviv)	no	yes					X	_			_	X	X	X	_		



	Name and location of vac-	Cat. A	Other							Year o	of Decla	ration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	13. Laboratory of leptospirosis with a museum of strains of microorganisms of the INM NAAS, laboratory of bacterial animal diseases (Kiev)	no	yes					_	_			_	_	x	x	X		
	14. PJSC Farmak (Kiev)	no	yes					X					X	X	X			
	1. Seqirus Vaccines Limited — former Novartis Vaccines and Diagnostics Limited (Liv- erpool)	no	yes	X	X	X	X	X	_	X	X	X	X	X	X	X	X	X
United	2. AstraZeneca Liverpool (registered in Companies House as MedImmune UK Ltd) (Liverpool)	no	yes	_	_	_	_	_	_	_	_	_	_	_	_	X	X	X
King- dom	3. Porton Biopharma Limited — former Public Health England—Porton — former Health Protection Agency (Salisbury)	An- thrax	no	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4. Merck BioReliance® Services (Glasgow) ²³	no	yes	_	_	_	_	_	_	_	_	_	_	_	_	X	X	X
	5. Valneva Scotland Ltd (Livingston)	no	yes											_		X	X	X
	6. MedImmune UK Ltd (Liverpool)	no	yes	X	X	X	X	X	X	X	X	X	X	X	X			
	7. Oxbox Manufacturing Facility (Oxford)	no	yes			_	_	_		_	_	_		_	_	_		X
	8. Cobra Biologics Limited (Staffordshire)	no	yes							_		_						X

 $^{^{23}}$ The facility produces the active viral ingredient for an Adenovirus vaccine Type 4 and Type 7 (2021, p. 41).



	Name and location of vac-	Cat. A	Other							Year	of Decla	ration						
Country	cine production facilities declared in CBM Form G	dis- eases ¹²	dis- eases	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
	1. Emergent Biosolutions (Lansing, MI)	An- thrax, Small- pox	no				X	X	X	X	X	X	X	X	X	X	X	X
	2. MassBiologics (Boston, MA)	no	yes				X	X	X	X	X	X	X	X	X	X	X	X
	3. MedImmune, LLC (Gaithersburg, MD)	no	yes				X	X	X	X	X	X	_	_	_	_	_	_
	4. Merck Sharp & Dohme Corp (North Wales, PA)	no	yes				X	X	X	X	X	X	X	X	X	X	X	X
	5. Organon Teknika Corporation, LLC (Durham, NC)	no	yes				X	X	X	X	X	X	X	X	X	X	X	X
USA	6. MCM Vaccine Company— Sanofi Pasteur, Inc. (Swiftwater, PA)	no	yes	_	_	_	_		_	_	_	_	_	_	_	X	X	X
	7. Sanofi Pasteur Biologics Co. (Cambridge, MA)	Small- pox	yes				X	X	X	X	X	X	X	X	X	_	_	_
	8. Wyeth Pharmaceuticals, Inc (New York, NY)	no	yes				X	X	X	X	X	X	X	X	X	X	X	X
	9. Barr Laboratories, Inc. (Forrest, VA)	no	yes				_		X	X	X	X	X	X	X	X	X	X
	10. Protein Sciences Corporation (Meriden, CT)	no	yes				_	_	_	X	x	X	X	X	X	X	x	X
	11. Sanofi Pasteur, Inc (Swiftwater, PA)	no	yes				X	X	X	X	X	X	X	X	X	X	X	X
	12. Seqirus Inc. (Holly Springs, NC)	no	yes				_	_	_	_	_	_	_	_		_	X	X
	Emergent Travel Health (Gaithersburg, MD)	no	yes				_	_	_	_	_	_	_	_	_	_	_	X

Research Group for Biological Arms Control

The aim of the Research Group is to contribute, through innovative research and outreach activities, to the universal prevention of biological weapons development, production and use. The focus of activities is twofold. Firstly, the Research Group contributes to preventing the erosion of the universal bioweapons prohibition by opposing norm—harming activities. Secondly, it develops new concepts and instruments for monitoring bioweapon relevant activities and for verifying and enforcing compliance with the norm against bioweapons.

Contact

Research Group for Biological Arms Control

C. F. v. Weizsäcker Centre for Science and Peace Research • University of Hamburg

Bogenallee 11 • 20144 Hamburg • Germany

Tel +49 40 42838 4383 • Fax +49 40 42838 3052 • E-Mail info@biological-arms-control.org

https://www.biological-arms-control.org/

Author

Mochament El Saer

Email: mochament.el_saer@kcl.ac.uk

